Due to their remarkable efficacy and safety profiles, EGFR tyrosine kinase inhibitors (TKIs) have been established for the first-line therapy in advanced EGFR-mutated NSCLC [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.